



Prescription Pharmaceutical Products

Product	Indication ^{1,2}	Territory						Partner
		Canada	Brazil	Argentina	Colombia	Mexico	Others	
Oncology/Hematology								
Tafasitamab	Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)		Submitted	Pre-registration	Pre-registration	Pre-registration	Pre-registration	Incyte
Pemigatinib	Metastatic cholangiocarcinoma		Pre-registration	Pre-registration	Pre-registration	Pre-registration	Pre-registration	Incyte
Akynzeo®	Prevention of chemotherapy-induced acute and delayed nausea and vomiting	Marketed	Marketed	Marketed			Pre-registration	Helsinn
Aloxi®	Prevention of acute nausea and vomiting associated with moderately and highly emetogenic cancer chemotherapy	Approved ³						Helsinn
Fostamatinib	Treatment of chronic immune thrombocytopenia		Pre-registration	Pre-registration	Pre-registration	Pre-registration	Pre-registration	Rigel
Nerlynx®	Extended adjuvant breast cancer and metastatic breast cancer	Marketed						Puma
Trelstar®	Advanced prostate cancer	Marketed						Debiopharm
Vidaza®	Myelodysplastic syndrome		Marketed					Celgene (BMS)
Abraxane®	Metastatic pancreatic cancer		Marketed					Celgene (BMS)
Halaven ®	Metastatic breast cancer and soft tissue sarcoma		Marketed	Marketed	Marketed		Marketed	Eisai
Lenvima®	Differentiated thyroid cancer and unresectable hepatocellular carcinoma		Marketed	Marketed	Marketed		Marketed	Eisai
Lenvima®	Advanced renal cell cancer		Marketed	Marketed			Marketed	Eisai
BGx								
Ladevina®	Multiple myeloma; myelodysplastic syndrome			Marketed	Marketed		Marketed	Own
Ladevina®	Mantle Cell Lymphoma; follicular lymphoma			Marketed			Marketed	Own
Zyvalix®	Metastatic prostate cancer			Marketed	Marketed		Marketed	Own
Karfib®	Relapsed or refractory multiple myeloma			Marketed			Approved	Own
Leprid®	Palliative treatment of advanced prostate cancer			Marketed				Own
Rembre®	Chronic myeloid leukemia			Marketed	Marketed		Marketed	Own
Infectious Diseases								
Ambisome®	Invasive fungal infection		Marketed					Gilead
Cresemba®	Invasive fungal infection		Marketed	Marketed	Marketed	Marketed	Marketed	Basilea
Impavido®	Leishmaniasis						Marketed	Own
Other Specialty								
Exelon®	Symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease	Marketed	Marketed	Marketed	Marketed	Marketed	Marketed	Own
Ibsrela®	IBS-C	Marketed						Ardelyx
Salofalk®	Ulcerative colitis			Marketed	Marketed		Marketed	Dr. Falk
Ursofalk®	Primary biliary cirrhosis			Marketed	Marketed		Marketed	Dr. Falk
Imvexxy™	Moderate-to-severe dyspareunia	Approved						TXMD
Bijuva™	Moderate-to-severe vasomotor symptoms due to menopause	Approved						TXMD
BGx								
Fibridoner®	Idiopathic pulmonary fibrosis			Marketed			Marketed	Own
Toliscrin® DPI	Pseudomonas aeruginosa lung infection in patients with cystic fibrosis			Marketed			Marketed	Own
Toliscrin® 1-2	Severe acute or resistant chronic infections due to colistin sensitive strains of gram-negative pathogenic bacilli			Marketed			Marketed	Own
Tobradosa Haler®	Chronic lung infections due to Pseudomonas aeruginosa			Marketed			Marketed	Own

¹ Products in "pre-registration" have not yet been submitted for regulatory review and products in "submitted" are currently under regulatory review. The indication for all products classified as "pre-registration" or "submitted" is the anticipated indication upon regulatory approval.

² Refer to the "Products" section of Management's Discussion and Analysis for the three and nine-month periods ended September 30, 2022.

³ Knight will begin commercial activities following a transition period from Helsinn current licensees.

Product Pipeline

Innovative

Product/Molecule	Licensor	Country	Therapeutic Area	Stage of development
Tafasitamab	Incyte	LATAM	Oncology/Hematology	Pre-Registration ¹
Pemigatinib	Incyte	LATAM	Oncology/Hematology	Pre-Registration
Fostamatinib	Rigel	LATAM	Oncology/Hematology	Pre-Registration
Bijuva™	TXMD	Canada	Other Specialty	Pre-Registration
Imvexxy™	TXMD	Canada	Other Specialty	Pre-Registration

¹ Submitted for regulatory review in Brazil

Branded Generics

Country	Therapeutic Area	Number of molecules	Stage of development	Expected launch year
Argentina	Oncology/Hematology	2	Development	2025
Argentina	Oncology/Hematology	1	Pending Launch	2023
Brazil	Oncology/Hematology	1	Development	2025
Brazil	Other Specialty	1	Development	2025
Colombia	Oncology/Hematology	2	Development	2025-2026
Colombia	Oncology/Hematology	1	Regulatory Review	2023
Colombia	Other Specialty	1	Development	2027
Chile	Oncology/Hematology	3	Development	2024
Mexico	Oncology/Hematology	1	Development	2027
Mexico	Other Specialty	1	Development	2025

